Listing 3 - Actual negotiations

Indication:

Metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations, first-line treatment (in combination with ipilimumab and 2 cycles of platinum-based chemotherapy)

Indication:

Unresectable malignant pleural mesothelioma (MPM) in adult patients who have not received prior systemic therapy for MPM (in combination with ipilimumab)

Indication:

Metastatic Castration-Resistant Prostate Cancer and Deleterious or suspected deleterious germline/somatic mutations in the HRR genes BRCA or ATM, monotherapy for the treatment of adult patients with mCRPC who have progressed following prior treatment with a NHA

Indication:

Carcinoma of the colon or rectum, metastatic, first-line treatment in combination with fluoropyrimidine based chemotherapy or patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen

Indication:

Psoriasis, moderate to severe plaque

Indication:

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, previously untreated with an ALK inhibitor, in adult patients

Indication:

Urothelial carcinoma (UC), first-line maintenance treatment of patients with locally advanced or metastatic whose disease has not progressed with first-line platinum-based induction chemotherapy

Indication:

Migraine, Chronic

Indication:

Acute myeloid leukemia (AML) newly diagnosed in patients who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy (in combination with azacitidine)

Indication:

Prevention of Migraine in Adults